In adherence to strict Non-Disclosure Agreements, Sedulo is unable to disclose identifiable information regarding our clients.
A leading pharmaceutical company needed a validated, continuously updated view of the competitive landscape across lab, point-of-care, and self-test diagnostics. Sedulo’s program combined landscape analysis, ongoing monitoring, and primary intelligence to support confident D2C strategy and expansion decisions.
A cybersecurity training provider needed clearer visibility into competitor products, pricing, and go-to-market strategy to sharpen its competitive positioning. Sedulo’s market intelligence program delivered detailed competitor profiles and sales battlecards that gave leadership the confidence to plan for long-term growth.
A leading software company needed a validated, ground-level view of a key HRM competitor across product, pricing, messaging, and go-to-market strategy. Sedulo designed a multi-method intelligence program, combining primary research, buy-side investigation, and customer observation to deliver the insights needed to sharpen positioning, strengthen sales enablement, and support strategic planning across the organization.
A pharmaceutical company needed more than a snapshot of competitor sales forces. Sedulo designed a continuous oncology intelligence program that tracked how seven key competitors were structuring, scaling, and deploying commercial resources, delivering the early signals needed to sharpen share-of-voice strategy and commercial planning.
A leading software provider partnered with Sedulo to gain a deeper understanding of competitor pricing, packaging, and market positioning. Through first-hand competitive intelligence and strategic analysis, the client identified opportunities to refine pricing strategy, strengthen market positioning, and support future growth.
A leading pharmaceutical company partnered with Sedulo Group to build a continuous competitive intelligence program tracking innovators, biosimilars, and emerging therapies across the rapidly evolving insulin market. The engagement combined ongoing competitor monitoring, primary intelligence, and quarterly landscape reporting to support stronger portfolio decisions and confident preparation for new market entrants.
